Seagen is a global biotechnology company dedicated to revolutionizing cancer care. We’re developing transformative therapies that make a meaningful difference in people’s lives.
As a pioneer in Antibody-Drug Conjugates (ADCs), Seagen has led the way in novel cancer therapeutics for more than 20 years. We’re committed to discovering safe and effective solutions to challenging clinical needs. Today, our research efforts are dedicated to advancing a pipeline of innovative therapies for solid tumours and blood-related cancers.
Seagen International GmbH Headquarters
Dammstrasse 23
6300 Zug
Switzerland
OfficeCH@seagen.com
Seagen Germany GmbH
Maximilianstrasse 13, 3 Stock
80539 München
DEUTSCHLAND
Telephone: +49 89 62 82 94 88
AG München HRB 248466 Deutschland
Geschäftsführer: Audrey Sherman, Lee J. Heeson
UID-Nr. DE326948917
For medical information contact
+41 (0)31 528 08 44
medinfoEU@seagen.com